DESI AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Cheever et al.

Serial No.: 09/493,480

Art Unit: 1643

Filing Date: January 28, 2000

Examiner: A. Holleran

For: HER-2/Neu Fusion Proteins

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

	Copies of the references are enclosed	
Ĺ	Copies of the references were submitted in parent application	Serial No
	(37 CFR 1.98(d))	
\mathbf{L}	A copy of the International Search Report which issued on Inter	national Application No.
	is submitted herewith. All of the publications cited in	
	are listed on the attached form PTO-1449 and Applicants unders	stand that copies have been
	supplied to the U.S. Patent Office by the International Bureau.	

A. [] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

[X] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. [] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
 - (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,

whichever occurs first.

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
 - [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- [] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,

/Virginia G. Campen/ Virginia G. Campen Attorney of Record Registration No. 37,092

Date: 22 June 2006 Customer No. 23347 GlaxoSmithKline Corporate Intellectual Property 5 Moore Drive, P.O. Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-1012

Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					SERIAL NO.			09/493,480 January 28, 2000		
MYUKMA	HON	ISCLUSURE 51	ALEMENI		PILING DATE APPLICANT			Cheever et al.		
							1643	CI AL		
					GROUP					
				EXAMINER			A. Holleran			
				ATTORNEY DOCKET NO.			CRX113US			
			U.S. F	ATENT D	OCUMENTS					
Examiner Patent Issue Date		Issue Date	Name		Class	Subclass	Filing Date If Appropriate			
	+		2/7/1989	Dalton et	a1					
	1.			 						
	2.	5,723,130	3/10/1998	Cheever e						
	3.	5,726,023	9/1/1998	Cheever e						
	4.	5,801,005	9/1/1998	Plowman		-				
	5.	5,811,098	12/8/1998	Cheever e		-				
	6.	5,846,538				 				
	7.	5,869,445	2/9/1999	Cheever e		 				
	8.	5,876,712	3/2/1999	Cheever		├				
	9.	6,080,409	6/27/2000	Laus et al			\vdash			
	10.	6,146,632	11/14/2000	Momin ct			 			
	11.	6,270,769	8/7/2001	Raychaud			<u> </u>	 		
	12.	6,333,169	12/25/2001	Hudziak e				 		
	13.	6,664,370	12/16/2003	Cheever e						
	14.	6,734,172	5/11/2004	Scholler e		ļ	<u> </u>	<u> </u>		
	15.	6,942,862	9/13/2005	Cheever e						
	16.	6,953,573	10/11/2005	Cheever e						
	17.	7,005,498	2/28/2006	Steinaa et				ļ		
	18.	US2002/18766	2/14/2002	Roberts e						
	19.	US2002/155527	10/24/2002	Stuart et a	J					
				Γ						
			FOREIG	N PATEN	DOCUMENTS					
	T	Document	Publication	1				Translation		
	1	Number	Date] (Country	Class	Subclass	Yes No		
	20.	WO00/04927	2/3/2000	PCT		1				
	21.	WO00/20027	4/13/2000	PCT						
	22.	WO00/29582	5/25/2000	PCT						
	23.	WO00/44899	8/3/2000	PCT		1				
	24.	WO01/74855	10/11/2001	PCT						
	25.	WO91/02062	2/21/1991	PCT						
	26.	WO91/18926	12/12/1991	PCT		T .				
	27.	WO95/17210	6/29/1995	PCT						
	28.	WO96/02555	2/1/1996	PCT		†				
			6/20/1996			-				
	29.	WO96/18409	6/20/1996	PCT						
	29. 30.	WO96/18409 WO98/25574	6/18/1998	PCT PCT						
	29. 30. 31.	WO96/18409 WO98/25574 WO99/46988	6/18/1998 9/21/1999	PCT PCT PCT	-					
	29. 30.	WO96/18409 WO98/25574	6/18/1998	PCT PCT						
	29. 30. 31.	WO96/18409 WO98/25574 WO99/46988 WO99/57981	6/18/1998 9/21/1999 11/18/1999	PCT PCT PCT PCT	Title lowered D	ria Pasa Nor	nher Etc.)			
	29. 30. 31. 32.	WO96/18409 WO98/25574 WO99/46988 WO99/57981	6/18/1998 9/21/1999 11/18/1999	PCT PCT PCT PCT	Title, Journal-Di	ate, Page Nur	nber, Etc.)	9 (1995).		
	29. 30. 31. 32.	W096/18409 W098/25574 W099/46988 W099/57981	6/18/1998 9/21/1999 11/18/1999 AENTS (Includ	PCT PCT PCT PCT PCT An Idea W	hose Time Has Co	me?, J. NIH r	esearch 7:46-4	9 (1995).		
	29. 30. 31. 32. 33. 34.	W096/18409 W098/25574 W099/46988 W099/57981 OTHER DOCUM EZZEL et al., Ca	6/18/1998 9/21/1999 11/18/1999 MENTS (Includencer "Vaccines" Vaccines: The	PCT PCT PCT PCT PCT An Idea W	hose Time Has Co Analogy, Cancer B	me?, J. NIH r iotherapy 10(esearch 7:46-4 1):1-3 (1995).			
	29. 30. 31. 32.	WO96/18409 WO98/25574 WO99/46988 WO99/57981 OTHER DOCUN EZZEL et al., Ca SPITLER, Cance DISIS et al., Pept	6/18/1998 9/21/1999 11/18/1999 MENTS (Includencer "Vaccines" vaccines: The	PCT PCT PCT PCT PCT An Idea W Interferon lot Whole P	hose Time Has Co Analogy, Cancer B rotein, Vaccines E	me?, J. NIH r iotherapy 10(esearch 7:46-4 1):1-3 (1995).			
	29. 30. 31. 32. 33. 34. 35.	WO96/18409 WO98/25574 WO99/46988 WO99/57981 OTHER DOCUM EZZEL et al., Ca SPITLER, Cance DISIS et al., Pep	6/18/1998 9/21/1999 11/18/1999 MENTS (Includincer "Vaccines" r Vaccines: The did-Based, but https://doi.org/10/1999	PCT PCT PCT PCT PCT An Idea W Interferon Iot Whole P	hose Time Has Co Analogy, Cancer B rotein, Vaccines E 1-3158 (1996).	me?, J. NIH r iotherapy 10(licit Immunity	esearch 7:46-4 1):1-3 (1995). to HER-2/new	, an Oncogenic		
	29. 30. 31. 32. 33. 34.	WO96/18409 WO98/25574 WO99/46988 WO99/57981 OTHER DOCUM EZZEL et al., Ca SPITLER, Cance DISIS et al., Pepi Self-Protein, The	6/18/1998 9/21/1999 11/18/1999 MENTS (Includencer "Vaccines" TVaccines: The ide-Based, but No. 10 of Immunology with Francisco	PCT PCT PCT PCT PCT An Idea W Interferon A Iot Whole P Zy 156:315	hose Time Has Co Analogy, Cancer B rotein, Vaccines E 1-3158 (1996). Foreign Proteins C	me?, J. NIH r iotherapy 10(licit Immunity	esearch 7:46-4 1):1-3 (1995). to HER-2/neu	, an Oncogenic		
	29. 30. 31. 32. 33. 34. 35.	WO96/18409 WO98/25574 WO99/46988 WO99/57981 OTHER DOCUM EZZEL et al., Ca SPITLER, Cance DISIS et al., Pept Self-Protein, Front DISIS et al., Imm Antigens, The F/	6/18/1998 9/21/1999 11/18/1999 MENTS (Includencer "Vaccines" TVaccines: The ide-Based, but No. 10 of Immunology with Francisco	PCT PCT PCT PCT PCT An Idea W Interferon A Iot Whole P Zy 156:315	hose Time Has Co Analogy, Cancer B rotein, Vaccines E 1-3158 (1996).	me?, J. NIH r iotherapy 10(licit Immunity	esearch 7:46-4 1):1-3 (1995). to HER-2/neu	, an Oncogenic		
	33. 33. 34. 35.	WO96/18409 WO98/25574 WO99/46988 WO99/57981 OTHER DOCUM EZZEL et al., Ca SPITLER, Cance DISIS et al., Pep Self-Protein, The DISIS et al., Imm Antigens, The F/ 6, 1996.	6/18/1998 9/21/1999 11/18/1999 MENTS (Includencer "Vaccines" r Vaccines: The ide-Based, but N J. of Immunologumization with FASEB Journal 10	PCT PCT PCT PCT PCT PCT Ing Author, An Idea W Interferon Iot Whole P 2y 156:315 Iomologous (6):A1470 (hose Time Has Co Analogy, Cancer B rotein, Vaccines E 1-3158 (1996). Foreign Proteins C 1996) ABSTRAC	me?, J. NIH r iotherapy 10(licit Immunity Generates Imn I from Meetin	esearch 7:46-4 1):1-3 (1995). to HER-2/neu	, an Oncogenic		
	29. 30. 31. 32. 33. 34. 35.	WO96/18409 WO98/25574 WO99/46988 WO99/57981 OTHER DOCUM EZZEL et al., Ca SPITLER, Cance DISIS et al., Pep Self-Protein, The DISIS et al., Imm Antigens, The F/ 6, 1996.	6/18/1998 9/21/1999 11/18/1999 MENTS (Includencer "Vaccines" r Vaccines: The ide-Based, but N J. of Immunologumization with FASEB Journal 10	PCT PCT PCT PCT PCT PCT Ing Author, An Idea W Interferon Iot Whole P 2y 156:315 Iomologous (6):A1470 (hose Time Has Co Analogy, Cancer B rotein, Vaccines E 1-3158 (1996). Foreign Proteins C	me?, J. NIH r iotherapy 10(licit Immunity Generates Imm I from Meetin 71 (1997).	esearch 7:46-4 1):1-3 (1995). to HER-2/nev nunity Against ngs, New Orlea	"Self" Tumor ms, LA June 2-		
EXAMINE	29. 30. 31. 32. 33. 34. 35.	WO96/18409 WO98/25574 WO99/46988 WO99/57981 OTHER DOCUM EZZEL et al., Ca SPITLER, Cance DISIS et al., Pep Self-Protein, The DISIS et al., Imm Antigens, The F/ 6, 1996.	6/18/1998 9/21/1999 11/18/1999 MENTS (Includencer "Vaccines" r Vaccines: The ide-Based, but N J. of Immunologumization with FASEB Journal 10	PCT PCT PCT PCT PCT PCT Ing Author, An Idea W Interferon Iot Whole P 2y 156:315 Iomologous (6):A1470 (hose Time Has Co Analogy, Cancer B rotein, Vaccines E 1-3158 (1996). Foreign Proteins C 1996) ABSTRAC	me?, J. NIH r iotherapy 10(licit Immunity Generates Imm I from Meetin 71 (1997).	esearch 7:46-4 1):1-3 (1995). to HER-2/neu	"Self" Tumor ms, LA June 2-		
EXAMINE	29. 30. 31. 32. 33. 34. 35. 36.	WO96/18409 WO98/25574 WO99/46988 WO99/57981 OTHER DOCUM EZZEL et al., Ca SPITLER, Cance DISIS et al., Pep Self-Protein, The DISIS et al., Imm Antigens, The F/ 6, 1996.	6/18/1998 9/21/1999 11/18/1999 MENTS (Includencer "Vaccines" TVaccines: The ide-Based, but N J. of Immunologunization with FASEB Journal 10 EVER, Advances	PCT PCT PCT PCT PCT Ing Author, An Idea W Interferon Iot Whole P Sy 156:315 Omologous (6):A1470 (in Cancer I	hose Time Has Co Analogy, Cancer B rotein, Vaccines 1- 3158 (1996). Foreign Proteins (1996) ABSTRAC Research 71:343-3	me?, J. NIH r iotherapy 10(licit Immunity Generates Imn I from Meetin 71 (1997).	esearch 7:46-4 1):1-3 (1995). 7 to HER-2/neu nunity Against ngs, New Orlea	"Self" Tumor uns, LA June 2-		